Drug General Information (ID: DDIECSD96W)
  Drug Name Esmolol Drug Info Tocainide Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antihypertensive Agents Antiarrhythmic Agents
  Structure

 Mechanism of Esmolol-Tocainide Interaction (Severity Level: Moderate)
     Increased risk of bradycardia Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Esmolol Tocainide
      Mechanism Bradycardia Bradycardia
      Key Mechanism Factor 1
Factor Name Bradycardia
Factor Description Bradycardia is a slow heart rate in which the heart beats less than 60 times per minute. If the heart rate is very slow and the heart is not pumping enough oxygen-rich blood to the body, and you may feel dizzy, very tired or weak, and short of breath.
      Mechanism Description
  • Increased risk of bradycardia by the combination of Esmolol and Tocainide 

Recommended Action
      Management The concomitant use of tocainide and beta blockers should probably be avoided in patients with atrioventricular conduction abnormalities or sick sinus syndrome. This combination should be used cautiously in other patients, with careful dose titration and close clinical and electrocardiographic monitoring for efficacy and safety.

References
1 Rubino M, Jackson E "Severe paranoia with concomitant tocainide and propranolol therapy." Clin Pharm 1 (1982): 177-9
2 Ikram H "Hemodynamic and electrophysiologic interactions between antiarrhythmic drugs and beta blockers, with special reference to tocainide." Am Heart J 100 (1980): 1076-80
3 Roden DM, Woosley RL "Tocainide." N Engl J Med 315 (1986): 41-5